Allena Pharmaceuticals, Inc.: Chapter 11 case summary
ElevenFlo ·
Allena Pharmaceuticals’ liquidation plan became effective on June 20, 2023, following its confirmation in May, according to the effective-date notice Dkt. 330. The case’s remaining path is implementation of the liquidation plan; the filings identify no later dated milestone.
Allena Pharmaceuticals’ Chapter 11 liquidation plan became effective on June 20, 2023, after the court confirmed it on May 18, 2023, as reflected in the confirmation order Dkt. 316 and effective-date notice Dkt. 330. The remaining path is implementation of the liquidation plan; no later dated milestone is identified.
Allena filed for Chapter 11 on September 2, 2022, after setbacks in its clinical programs and difficulty raising capital. Its first-day declaration Dkt. 3 described the termination of a reloxaliase study following disappointing interim results and the decision not to advance its ALLN-346 program further given financial constraints. The company pursued an asset sale, and the court later authorized the sale of certain assets to Glyscend Dkt. 244.
Before the filing, Allena settled its outstanding balance with secured lender Pontifax and obtained releases of its liens. The solicitation disclosure statement Dkt. 279 states that Pontifax retained a contingent unsecured payment right if material creditors received more than 25% of amounts owed or equity received a cash distribution. Allena estimated approximately $3.4 million in unsecured contractual and trade debt at the petition date.
Sources
- Dkt. 3First Day DeclarationFiled Sep 2, 2022Sep 2, 2022
- Dkt. 244Order (I) Approving Glyscend Asset Purchase Agreement and Authorizing the Sale of Certain Assets of the Debtor Outside the Ordinary Course of Business, (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims, Encumbrances and Interests, (III) Authorizing the Assumption & Assignment of Executory Contracts, and (IV) Granting Related Relief (related document(s)[14], [86], [224], [225], [234], [235]) Order Signed on 3/20/2023. (Attachments: # (1) Exhibit A) (Mml)Filed Mar 20, 2023Mar 20, 2023
- Dkt. 279Disclosure Statement for the Plan of Liquidation (Solicitation Version) Filed by Allena Pharmaceuticals, Inc. (Jenner, Nicolas)Filed Apr 12, 2023Apr 12, 2023
- Dkt. 316Findings of Fact, Conclusions of Law, and Order (I) Confirming Plan of Liquidation of Allena Pharmaceuticals, Inc. Pursuant to Chapter 11 of the Bankruptcy Code and (II) Approving the Disclosure Statement on a Final Basis (related document(s)[241], [242], [243], [267], [268], [269], [278], [279], [293], [305], [309]) Signed on 5/18/2023. (Attachments: # (1) Exhibit A # (2) Exhibit B) (Mml)Filed May 18, 2023May 18, 2023
- Dkt. 330Notice of Effective Date (Notice of (A) Entry of the Order (I) Approving the Disclosure Statement on A Final Basis and (II) Confirming the Amended Plan of Liquidation of Allena Pharmaceuticals, Inc. Pursuant to Chapter 11 of the Bankruptcy Code; (B) the Effective Date Thereof; and (C) Certain Deadlines) (related document(s)[316]) Filed by Allena Pharmaceuticals, Inc.. (Jenner, Nicolas)Filed Jun 20, 2023Jun 20, 2023